R-CHOP protocol: Clinical Trials

13 trials of R-CHOP protocol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 unknown, 3 completed, 2 active not recruiting, 1 enrolling by invitation. 13 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 313Unknown 5, Completed 3, Active not recruiting 2, Enrolling by invitation 1, Recruiting 1, Withdrawn 1

Follow R-CHOP protocol: new trials by email Literature Review of R-CHOP protocol trials Research Report on R-CHOP protocol

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Surovatamig, R-CHOP, R-CVP - Untreated Follicular Lymphoma
Phase 3RecruitingAstraZeneca10182024-08-072026-10-21
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
R-CHOP, Decitabine in combination with R-CHOP - Lymphoma, Large-Cell, Diffuse
Phase 3Enrolling by invitationSecond Affiliated Hospital of Nanchang University802024-07-012026-01-16
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles - Follicular Lymphoma (FL)
Phase 3Active not recruitingNovartis Pharmaceuticals1092023-10-022026-04-17
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Orelabrutinib and R-CHOP, R-CHOP - Treatment-naїve Mantle Cell Lymphoma
Phase 3CompletedBeijing InnoCare Pharma Tech Co., Ltd.32021-12-222026-03-31
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A) - Follicular Lymphoma
Phase 3Active not recruitingFondazione Italiana Linfomi - ETS6052021-12-012026-06-26
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
G-CHOP, R-CHOP - Diffuse Large B-Cell Lymphoma, Unspecified Site
Phase 3UnknownNanjing Yoko Biomedical Co., Ltd.3602018-12-282024-02-20
Thalidomide Combined With R-CHOP in Newly Diagnosed,Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients
Thalidomide combined with R-CHOP, R-CHOP - Thalidomide
Phase 3UnknownFudan University1622017-08-222017-10-24
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
R-CHOP, R-CHOP / R-HAD, Rituximab - Mantle Cell Lymphoma
Phase 3CompletedThe Lymphoma Academic Research Organisation6232013-11-012025-03-05
Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas
(R-)CHOP protocol, B-ALL protocol - Lymphoma, High-grade
Phase 3CompletedUniversity Hospital, Essen10732007-11-012017-05-05
Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma
R-CVP, R-CHOP, R-FM - Follicular Lymphoma
Phase 3UnknownFondazione Italiana Linfomi - ETS5342005-12-012011-02-15
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
Rituximab, Cyclophosphamide, Doxorubicin - Lymphoma, Mantle-Cell
Phase 3UnknownEuropean Mantle Cell Lymphoma Network3602004-07-012012-09-10
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
Rituximab, Cyclophosphamide, Doxorubicin - Lymphoma, Mantle-Cell
Phase 3UnknownEuropean Mantle Cell Lymphoma Network5702004-01-142017-03-07
R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL
R-CHOP, Radiotherapy - Diffuse Large B-cell Lymphoma
Phase 3WithdrawnAsan Medical Center2016-02-23

Conditions studied

Lymphoma, Follicular (4)  ·  Lymphoma, Large B-Cell, Diffuse (4)  ·  Lymphoma, Mantle-Cell (3)  ·  Lymphoma, Non-Hodgkin (2)  ·  Recurrence (1)

Sponsors

European Mantle Cell Lymphoma Network (2)  ·  Fondazione Italiana Linfomi - ETS (2)  ·  Asan Medical Center (1)  ·  AstraZeneca (1)  ·  Beijing InnoCare Pharma Tech Co., Ltd. (1)  ·  Fudan University (1)  ·  Nanjing Yoko Biomedical Co., Ltd. (1)  ·  Novartis Pharmaceuticals (1)  ·  Second Affiliated Hospital of Nanchang University (1)  ·  The Lymphoma Academic Research Organisation (1)  ·  University Hospital, Essen (1)

Countries

China (5)  ·  Germany (5)  ·  Poland (5)  ·  France (4)  ·  Italy (4)  ·  Czechia (3)  ·  South Korea (3)  ·  Spain (3)  ·  Australia (2)  ·  Belgium (2)  ·  Canada (2)  ·  Denmark (2)  ·  Hungary (2)  ·  Netherlands (2)  ·  Taiwan (2)

Top investigators

Chan Cheah, MBBS FRACP FRCPA DMSc (1)  ·  Fang-Fang Lv (1)  ·  Hanneke C. Kluin-Nelemans, PhD (1)  ·  Johanna Cornelia Kluin-Nelemans, Prof. Dr. (1)  ·  Martin Dreyling, PhD (1)  ·  Martin Dreyling, Prof. Dr. (1)  ·  Massimo Federico, PhD (1)  ·  Olivier Hermine, PhD (1)  ·  Stefano Luminari, MD (1)  ·  Ulrich Duehrsen, Prof. Dr. (1)  ·  Vincent Ribrag, Dr (1)  ·  Wolfgang Hiddemann, PhD (1)

Results publications

PMID 20032498, PMID 24687837, PMID 19863177, PMID 20644097, PMID 22873532, PMID 25596266, PMID 26022239, PMID 27313086, PMID 29095677, PMID 29750632, PMID 30125215, PMID 31710995, PMID 31804876, PMID 32022621, PMID 33928400, PMID 34708297, PMID 36469833, PMID 37992261, PMID 40397196, PMID 40453056

NIH funding

2023 (2)